Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Heartbeam Inc. Warrant (BEATW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BEATW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 14.02% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 19217 | Beta - | 52 Weeks Range 0.17 - 1.23 | Updated Date 02/24/2025 |
52 Weeks Range 0.17 - 1.23 | Updated Date 02/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.31% | Return on Equity (TTM) -164.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5185854 |
Shares Outstanding - | Shares Floating 5185854 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Heartbeam Inc. Warrant
Company Overview
History and Background
Heartbeam Inc. is a development stage company focused on transforming cardiac care through the power of wearable technology and cloud-based AI. The company's focus is on developing a 3D vector electrocardiogram (3D VECG) platform for detection of heart attacks.
Core Business Areas
- Electrocardiogram (ECG) Technology: Focuses on the development and commercialization of advanced ECG solutions, including its core 3D VECG platform for early detection of cardiac events.
Leadership and Structure
The leadership team consists of experienced professionals in the medical device industry. The organizational structure is typical of a development stage medical device company, focusing on research and development, regulatory approvals, and early-stage commercialization efforts.
Top Products and Market Share
Key Offerings
- HeartBeam AIMIGo: A credit card-sized personal ECG device to record 12-lead ECGs for suspected heart attack. Still pending FDA Clearance, competitors include AliveCor, Biobeat, and other consumer ECG devices. Market share is currently negligible as it is in development stage and awaiting FDA clearance.
Market Dynamics
Industry Overview
The cardiac monitoring market is experiencing growth due to increasing prevalence of heart disease, aging population, and technological advancements in wearable devices and remote patient monitoring.
Positioning
Heartbeam aims to disrupt the cardiac monitoring market with its 3D VECG technology, offering a potentially more accurate and convenient solution for detecting cardiac events compared to traditional methods.
Total Addressable Market (TAM)
The global cardiac monitoring market is projected to reach billions of dollars. Heartbeam's positioning focuses on the at-home and remote patient monitoring segments, allowing them to address a significant portion of the TAM.
Upturn SWOT Analysis
Strengths
- Proprietary 3D VECG Technology
- Potential for Early and Accurate Heart Attack Detection
- Experienced Management Team
Weaknesses
- Development Stage Company with No Current Revenue
- Reliance on Regulatory Approvals (FDA)
- Competition from Established Medical Device Companies
Opportunities
- Growing Cardiac Monitoring Market
- Increasing Demand for Remote Patient Monitoring
- Potential for Partnerships with Healthcare Providers
Threats
- Regulatory Hurdles and Delays
- Technological Advancements by Competitors
- Market Acceptance of New Technology
Competitors and Market Share
Key Competitors
- ALVR
- BMRA
- OM
- PRVA
Competitive Landscape
Heartbeam faces competition from established medical device companies with greater resources and market presence. Its advantage lies in its proprietary 3D VECG technology and potential for improved accuracy in heart attack detection.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth due to development stage.
Future Projections: Future growth is contingent on FDA approval and commercial adoption of the HeartBeam AIMIGo and associated technologies. Analyst projections are speculative at this point.
Recent Initiatives: Focus on clinical trials, regulatory submissions, and strategic partnerships.
Summary
Heartbeam Inc. is a high-risk, high-reward development stage company. Its success hinges on obtaining regulatory approvals and achieving market adoption of its 3D VECG technology. The company faces strong competition from established players and needs to manage its cash flow effectively. Potential exists for partnerships and acquisitions if their technology proves successful. The company shows promise, but is very risky because it's in development stage.
Similar Companies
ALVR
Allovir Inc
ALVR
Allovir Inc
BMRA
Biomerica Inc
BMRA
Biomerica Inc
DXCM
DexCom Inc
DXCM
DexCom Inc
ILMN
Illumina Inc
ILMN
Illumina Inc
OM
Outset Medical Inc
OM
Outset Medical Inc
PRVA
Privia Health Group Inc
PRVA
Privia Health Group Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (if available)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heartbeam Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-11 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 15 | Website |
Full time employees 15 | Website | ||
HeartBeam, Inc., a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company develops three-dimensional (3D)-vector electrocardiogram (ECG) platform for heart attack detection. It is developing HeartBeam AIMI software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack; and HeartBeam AIMIGo, a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.